Barinthus Biotherapeutics PLC Sponsored ADR (BRNS)
(Delayed Data from NSDQ)
$2.30 USD
+0.15 (6.91%)
Updated May 22, 2024 03:57 PM ET
After-Market: $2.26 -0.04 (-1.74%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Barinthus Biotherapeutics PLC Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 142 | 194 | 214 | 43 | 11 |
Receivables | 5 | 10 | 6 | 3 | 4 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 10 | 8 | 6 | 1 | 1 |
Total Current Assets | 157 | 213 | 227 | 48 | 16 |
Net Property & Equipment | 12 | 8 | 2 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 37 | 40 | 44 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 0 | 0 |
Total Assets | 215 | 270 | 281 | 51 | 19 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 4 | 2 | 5 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 9 | 8 | 8 | 3 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 13 | 12 | 11 | 8 | 6 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 4 | 8 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 45 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3 | 3 | 2 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 34 | 34 |
Total Liabilities | 28 | 27 | 28 | 88 | 41 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 387 | 380 | 369 | 20 | 16 |
Retained Earnings | -177 | -103 | -109 | -56 | -38 |
Other Equity | -23 | -33 | -8 | -1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 187 | 243 | 253 | -37 | -22 |
Total Liabilities & Shareholder's Equity | 215 | 270 | 281 | 51 | 19 |
Total Common Equity | 187 | 243 | 253 | -37 | -22 |
Shares Outstanding | 38.57 | 37.30 | 34.80 | NA | NA |
Book Value Per Share | 4.85 | 6.52 | 7.26 | 0.00 | 0.00 |
Fiscal Year End for Barinthus Biotherapeutics PLC Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 130 | 142 | 160 | 173 | 191 |
Receivables | 5 | 5 | 4 | 3 | 3 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 8 | 10 | 7 | 8 | 6 |
Total Current Assets | 143 | 157 | 171 | 185 | 201 |
Net Property & Equipment | 12 | 12 | 12 | 14 | 13 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 37 | 37 | 38 | 39 | 40 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 199 | 215 | 230 | 246 | 262 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 2 | 5 | 2 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 8 | 9 | 12 | 9 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 13 | 13 | 19 | 12 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 2 | 2 | 3 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3 | 3 | 3 | 3 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 27 | 28 | 34 | 29 | 28 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 389 | 387 | 386 | 386 | 384 |
Retained Earnings | -192 | -177 | -159 | -145 | -121 |
Other Equity | -25 | -23 | -31 | -23 | -29 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 172 | 187 | 196 | 217 | 234 |
Total Liabilities & Shareholder's Equity | 199 | 215 | 230 | 246 | 262 |
Total Common Equity | 172 | 187 | 196 | 217 | 234 |
Shares Outstanding | 38.92 | 38.57 | 38.50 | 38.30 | 38.30 |
Book Value Per Share | 4.42 | 4.85 | 5.08 | 5.68 | 6.10 |